Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « AbsEn.i » - entrée « moderate »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
models < moderate < moderated  Facettes :

List of bibliographic references indexed by moderate

Number of relevant bibliographic references: 175.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000050 (2020) Daichi Fukaya [Japon] ; Tsutomu Inoue [Japon] ; Yuta Kogure [Japon] ; Hiroshi Kajiyama [Japon] ; Keisuke Ishizawa [Japon] ; Takeru Seto [Japon] ; Hajime Hasegawa [Japon] ; Toshihide Mimura [Japon] ; Hirokazu Okada [Japon]Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases.
000143 (2020) Eduardo Mysler [Argentine] ; Mario H. Cardiel [Mexique] ; Ricardo M. Xavier [Brésil] ; Alejandra L Pez ; Allan Ramos-Esquivel [Costa Rica]Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb Study.
000155 (2020) Meng Xu ; Congcong Liu ; Lishuang Guo ; Sirui YangSevere sepsis caused by serious gastrointestinal infection in sJIA patients treated with IL-6 receptor antagonist: a case report
000177 (2020) Kaveh Hajifathalian ; Srihari Mahadev ; Robert E. Schwartz ; Shawn Shah ; Kartik Sampath ; Felice Schnoll-Sussman ; Robert S. Brown Jr ; David Carr-Locke ; David E. Cohen ; Reem Z. SharaihaSARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant
000260 (2020) Ruksana HudaNew Approaches to Targeting B Cells for Myasthenia Gravis Therapy
000274 (2020) Meng Hsuan Kuo [Taïwan] ; Chih-Wei Tseng [Taïwan] ; Chi-Hui Lee [Taïwan] ; Chien-Hsueh Tung [Taïwan] ; Kuo-Chih Tseng [Taïwan] ; Ning-Sheng Lai [Taïwan]Moderate Risk of Hepatitis B Virus Reactivation in HBsAg−/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis
000292 (2020) Fujun Peng [République populaire de Chine] ; Lei Tu [République populaire de Chine] ; Yongshi Yang [République populaire de Chine] ; Peng Hu [République populaire de Chine] ; Runsheng Wang [République populaire de Chine] ; Qinyong Hu [République populaire de Chine] ; Feng Cao [République populaire de Chine] ; Taijiao Jiang [République populaire de Chine] ; Jinlyu Sun [République populaire de Chine] ; Guogang Xu [République populaire de Chine] ; Christopher Chang [États-Unis]Management and Treatment of COVID-19: The Chinese Experience
000309 (2020) Florian Moretto ; François-Xavier Catherine ; Clémentine Esteve ; Mathieu Blot [France] ; Lionel Piroth [France]Isolated Anti-HBc: Significance and Management
000322 (2020) Rui Liu [République populaire de Chine] ; Bin Xu [République populaire de Chine] ; Shengqing Yu [République populaire de Chine] ; Jingfeng Zhang [République populaire de Chine] ; Huawei Sun [République populaire de Chine] ; Chuanmin Liu [République populaire de Chine] ; Fengying Lu [République populaire de Chine] ; Qunxing Pan [République populaire de Chine] ; Xiaofei Zhang [République populaire de Chine]Integrated Transcriptomic and Proteomic Analyses of the Interaction Between Chicken Synovial Fibroblasts and Mycoplasma synoviae
000334 (2020) Amin Gasmi [France] ; Sadaf Noor [Pakistan] ; Torsak Tippairote [Thaïlande] ; Maryam Dadar [Iran] ; Alain Menzel [France] ; Geir Bj Rklund [Norvège]Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic
000397 (2020) Andrei A. Deviatkin ; Yulia A. Vakulenko [Russie] ; Ludmila V. Akhmadishina ; Vadim V. Tarasov ; Marina I. Beloukhova ; Andrey A. Zamyatnin Jr. [Russie] ; Alexander N. LukashevEmerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy
000424 (2020) Salah Ghabri [France] ; Aymeric Binard [France] ; Yves-Marie Pers [France] ; Franck Maunoury [France] ; J Jaime Caro [États-Unis]Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France.
000546 (2020) Marcus R. Pereira [États-Unis] ; Sumit Mohan [États-Unis] ; David J. Cohen [États-Unis] ; S Ali Husain [États-Unis] ; Geoffrey K. Dube [États-Unis] ; Lloyd E. Ratner [États-Unis] ; Selim Arcasoy [États-Unis] ; Meghan M. Aversa [États-Unis] ; Luke J. Benvenuto [États-Unis] ; Darshana Dadhani [États-Unis] ; Sandip Kapur [États-Unis] ; Lorna M. Dove [États-Unis] ; Robert S. Brown [États-Unis] ; Russell E. Rosenblatt [États-Unis] ; Benjamin Samstein [États-Unis] ; Nir Uriel [États-Unis] ; Maryjane A. Farr [États-Unis] ; Michael Satlin [États-Unis] ; Cathy B. Small [États-Unis] ; Thomas Walsh [États-Unis] ; Rosy Priya Kodiyanplakkal [États-Unis] ; Benjamin A. Miko [États-Unis] ; Justin G. Aaron [États-Unis] ; Demetra S. Tsapepas [États-Unis] ; Jean C. Emond [États-Unis] ; Elizabeth C. Verna [États-Unis]COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter.
000618 (2019-06-12) Alain Saraux [France] ; Thomas Barnetche [France] ; Guy Baudens [France] ; Isabelle Idier [France] ; Flore Delaporte [France] ; Pascal Hilliquin [France]Subcutaneous tocilizumab in monotherapy or in combination with csdmard in patients with moderate to severe rheumatoid arthritis: observational study to describe real-world drug retention rate at 12 months.
000631 (2019) P M Villiger [Suisse][Large-vessel vasculitis-giant cell and Takayasu arteritis].
000733 (2019) Deeti J. Pithadia ; Kelly A. Reynolds ; Erica B. Lee ; Wilson Liao ; Jashin J. WuTildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
000831 (2019) Laura Bazzichi [Italie] ; Francesca Nacci [Italie] ; Luigi Sinigaglia [Italie] ; Laura Bianchino [Italie] ; Roberto Caporali [Italie]Subcutaneous tocilizumab alone or with a csDMARD in rheumatoid arthritis patients: subanalysis of Italian data from a multicenter phase IIIb/IV trial.
000848 (2019) Michael A. Ghebre ; Pee Hwee Pang [Singapour] ; Dhananjay Desai ; Beverley Hargadon ; Chris Newby ; Joanne Woods ; Laura Rapley ; Suzanne E. Cohen ; Athula Herath ; Erol A. Gaillard ; Richard D. May [Royaume-Uni] ; Chris E. BrightlingSevere exacerbations in moderate-to-severe asthmatics are associated with increased pro-inflammatory and type 1 mediators in sputum and serum
000858 (2019) Gerard Bruin ; Anke Hasselberg ; Irina Koroleva ; Julie Milojevic ; Claudio Calonder ; Rachel Soon ; Ralph Woessner ; David M. Pariser ; Bruno Boutouyrie-DumontSecukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis
000933 (2019) Rajeshwari Punekar ; Jeannie Choi ; Susan Boklage ; Melitza Iglesias-Rodriguez ; Kamala NolaReal-World Dose Modification Patterns of Subcutaneous Tocilizumab Among Patients with Rheumatoid Arthritis
000A50 (2019) Manuel Camean-Castillo [Espagne] ; Vicente Gimeno-Ballester [Espagne] ; Esmeralda Rios-Sanchez [Espagne] ; Silvia Fenix-Caballero [Espagne] ; Miguel Vázquez-Real [Espagne] ; Emilio Alegre-Del Rey [Espagne]Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i -k "moderate" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/AbsEn.i  \
                -Sk "moderate" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    moderate
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021